Phase II Study of Fluconazole for Lymphocutaneous & Visceral

Clinical Trial Description

PROTOCOL OUTLINE:

Patients are treated with daily oral fluconazole for up to 24 months. Follow-up continues for at least 1 year. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Primary Purpose: Treatment

Related Conditions & MeSH terms

Sporotrichosis

See also
Status	Clinical Trial	Phase
Completed	`NCT00004808` - Phase II Pilot Study of Fluconazole for Histoplasmosis, Blastomycosis, and Sporotrichosis	Phase 2
Not yet recruiting	`NCT06300138` - Antifungal Agents and Infrared Thermotherapy Alone or in Combination in the Treatment of Sporotrichosis	N/A
Completed	`NCT00004811` - Phase I/II Study of Itraconazole for Blastomycosis, Histoplasmosis, and Sporotrichosis	Phase 1/Phase 2

See also

Status

Clinical Trial

Phase

Completed

NCT00004808 - Phase II Pilot Study of Fluconazole for Histoplasmosis, Blastomycosis, and Sporotrichosis

Phase 2

Not yet recruiting

NCT06300138 - Antifungal Agents and Infrared Thermotherapy Alone or in Combination in the Treatment of Sporotrichosis

N/A

Completed

NCT00004811 - Phase I/II Study of Itraconazole for Blastomycosis, Histoplasmosis, and Sporotrichosis

Phase 1/Phase 2

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT00004938
Study type	Interventional
Source	Office of Rare Diseases (ORD)
Contact
Status	Completed
Phase	Phase 2
Start date	August 1996
Completion date	August 1996

Phase II Study of Fluconazole for Lymphocutaneous and Visceral Sporotrichosis

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms